Skip to content
Fibrocor Therapeutics

Fibrocor Therapeutics

  • Home
  • About Us
    • Leadership
  • Pipeline
    • Discovery
  • Careers
  • Resources
  • News
  • Contact
Search
Fibrocor Therapeutics
Search Toggle menu
June 23, 2023Publications

Piper/Sandler BioInsights, March 31, 2023 Respiratory Industry Report

Read report here

June 23, 2023News

Fibrocor Therapeutics Conference Participation 2023

Networking, partnering and debating critical issues: BioEurope: Basel, Switzerland, March 2023 BioEquity Dublin, Ireland May 2023 –Presenter Bio International Convention, Boston, MA, June 202 Jeffries Global Healthcare Conference, New York, NY June  2023

May 18, 2023September 18, 2024Publications

Getting to the Core of Fibrosis

FIBROCOR WAS FOUNDED IN 2017 BY TORONTO INNOVATION ACCELERATION PARTNERS (TIAP) AND EVOTEC INT’L to develop the translational science capabilities coming from laboratories at St. Michael’s Hospital in Toronto, Canada.

October 1, 2021June 15, 2023News

Piper Sandler Lung Day Conference

Oct 1, 2021 For Immediate Release – Fibrocor Therapeutics Inc, a precision medicine company developing first in class drugs for IPF and other fibrotic diseases, is participating at the upcoming Piper Sandler Lung Day conference […]

October 20, 2020June 15, 2023News

Fibrocor is pleased to be presenting at TSX Life Sciences Investor Day

Fibrocor is pleased to be presenting at TSX Life Sciences Investor Day

January 15, 2020June 15, 2023News

Fibrocor and Galapagos Sign Expanded Collaboration in Fibrosis

Mechelen, Belgium and Toronto, Canada; 15 January 2020, 7.30 CET – Galapagos NV (Euronext & NASDAQ: GLPG) and Fibrocor Therapeutics Inc. (Fibrocor) today announced an expanded collaboration focused on novel targets in fibrosis, with Galapagos […]

December 30, 2018June 15, 2023News

Fibrocor and Galapagos Sign Partnership in Fibrosis

Mechelen, Belgium; December 2018, 22.01 CET – Fibrocor Therapeutics L.P. (Fibrocor), a privately held Canadian company, and Galapagos NV (Euronext & NASDAQ: GLPG) announced a global partnership focused on a novel target for idiopathic pulmonary […]

Posts pagination

< 1 2

661 University Ave, Suite 1300, Toronto, Ontario, Canada M5G 0B7 || 647.447.2047  || info@fibrocor.com

Our Newsletter

Subscribe

* indicates required



Site Navigation

  • Home
  • About Us
    • Leadership
  • Pipeline
    • Discovery
  • Careers
  • Resources
  • News
  • Contact
  • Partners

LinkedIn


YouTube
Copyright © 2025 Fibrocor Therapeutics, Inc
Fibrocor Therapeutics
Close menu
  • Home
  • About Us
    • Leadership
  • Pipeline
    • Discovery
  • Careers
  • Resources
  • News
  • Contact